Quince Therapeutics board to turn over three seats ahead of October 6 special meeting

Quince Therapeutics, Inc. disclosed in an 8-K filed for an event dated September 30, 2026 that three of its directors, June Bray, David Lamond and Christopher Senner, tendered conditional resignations from the Board of Directors, effective as of two business days following the conclusion of the Company's Special Meeting of Stockholders, which will be held on October 6, 2026, and contingent upon the approval by the Company's stockholders of three proposals.¹

Those proposals cover approval of share issuances upon conversion of Series C Non-Voting Convertible Preferred Stock and exercise of related warrants and options tied to Orphai Therapeutics, LLC, which could represent more than 20% of outstanding common stock and, together with management and board changes, could result in a change of control under Nasdaq rules, a related minimum price proposal under Nasdaq Listing Rule 5635(d), and an amendment raising authorized common shares from 250,000,000 to 275,000,000.¹ The filing states the resigning directors' decisions were not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.¹

On October 1, 2026, the board approved conditional appointments of four incoming directors, Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise, effective as of the Effective Time.¹ Bonuccelli previously served as Chief Medical Officer of Bellus Health, acquired by GSK plc in 2023, from August 2019 to April 2024, where she advanced an asset for refractory chronic cough into Phase 3 prior to the acquisition.¹ Patterson most recently served as Executive Vice President, Chief Business Officer and Chief Financial Officer of Zymeworks, Inc. from September 2024 to January 2026.¹ Valentine has worked at Hyman, Phelps & McNamara, P.C., a law firm specializing in food and drug law, since January 2023.¹ Wise previously served at Insmed Incorporated from February 2014 to April 2025, including as Chief Commercial Officer from May 2022 to April 2025, where he led the global launch of ARIKAYCE.¹

The company said it intends to enter into its standard form of indemnification agreement with each of the Incoming Directors upon the effectiveness of their respective appointments.¹ The filing was signed by Chief Executive Officer Dirk Thye on October 2, 2026.